Non-profit website: free to use. No fees from patients, hospitals or doctors. Not an agency. · Free · Not an agencyLearn more
General & GI surgery · Beijing Shijitan Hospital · Beijing

Dr. Li Yanping李艳萍

Chief Physician · Associate Professor
Department head

Summary compiled from public information, updated 18 Nov 2026. It has not been checked against the hospital website yet. Confirm details with the hospital before you travel.

Dr. Li Yanping

Professional overview

Dr. Li Yanping is a Chief Physician and Director of the Breast Surgery Department at Beijing Shijitan Hospital, specializing in the diagnosis and treatment of breast diseases.

SpecialtyGeneral & GI surgery
Clinical titleChief Physician
Academic rolesAssociate Professor, Master's Supervisor
DepartmentBreast Surgery
HospitalBeijing Shijitan Hospital
CityBeijing
Hospital roleDirector of the Breast Surgery Department

Department leadership

Department head

A department head is an organisational role. “Chief Physician” is a clinical rank; the two are listed separately.

Areas of focus

Breast cancerSpecializes in breast-conserving surgery, modified radical mastectomy, sentinel lymph node biopsy, and comprehensive treatment including neoadjuvant, adjuvant, endocrine, and targeted therapy.
Minimally invasive treatment of benign breast tumorsPerforms minimally invasive procedures for benign breast tumors, especially for suspicious malignant lesions not palpable by ultrasound or mammography.
Sentinel lymph node biopsyUses sentinel lymph node biopsy as an alternative to axillary lymph node dissection.
Wire localization surgeryPerforms ultrasound- and mammography-guided wire localization surgery for non-palpable breast lesions.

Background

  • 2008Principal Investigator of a Ministry of Health-funded project on clinical application of fluorescence in situ hybridization (FISH) for HER-2/neu gene amplification detection in breast cancer.
  • 2010Co-investigator of a National Natural Science Foundation of China (NSFC) project on tripterygium toxicity-efficacy correlation mediated by estrogen receptor.
  • 2013–2015Co-investigator of a Beijing Municipal Science and Technology Commission project on ER pathway-based herbal formula reversing endocrine therapy resistance in breast cancer.
  • 2015–2018Major participant in a clinical study on selective Treg inhibition combined with endocrine therapy for elderly metastatic breast cancer patients intolerant to or failing chemotherapy.
  • 2018–2021Co-investigator of a 'Capital Clinical Characteristic Application Research' project on PD-1/PD-L1 expression in peripheral blood of breast cancer patients.
  • 2019–2020PI of a multicenter, randomized, double-blind, parallel-controlled Phase III trial comparing trastuzumab deruxtecan plus docetaxel versus trastuzumab plus docetaxel in patients with HER2-overexpressing metastatic breast cancer.
  • 2020–2021PI of a Phase I clinical study evaluating the safety and tolerability of SHR-A1201 in patients with HER2-positive advanced breast cancer.
  • 2020–2021PI of a randomized Phase III trial comparing entinostat versus placebo combined with endocrine therapy in patients with hormone receptor-positive advanced breast cancer.
  • 2021Principal Investigator (PI) of a multicenter, randomized, open-label, single-dose, two-cycle, crossover bioequivalence trial of liposomal doxorubicin hydrochloride in female patients with breast cancer.

Experience & recognition

  • Completed nearly 10,000 breast cancer radical surgeries
  • Editor-in-chief of 'Training Manual for Early Breast Cancer Screening' (China Women's Development Foundation, 2014)
  • Co-editor of the humanistic book 'You Are Not Alone' (published overseas in 2024)
  • Recipient of the 'Anti-Cancer Guardian' award (2017, Breast Cancer Lehuozhe Alliance)
  • Recipient of hospital-level awards for innovation in sentinel lymph node biopsy and wire localization biopsy (2011, 2013)
  • Recipient of hospital-level awards for mammary ductoscopy-assisted foreign body removal (2011) and mammary ductoscopy application in nipple discharge (2012)
  • Recipient of the Liaoning Provincial Science and Technology Progress Third Prize for research on biological prognostic indicators in lymph node-negative breast cancer

Professional roles

  • Member, Breast Cancer Prevention and Control Expert Committee, Women's Health Promotion Special Fund, China Health Promotion Foundation
  • Vice Chair, Health Management Professional Committee, Beijing Society for Breast Disease Prevention and Treatment
  • Vice Chair, Mass Work Committee, Beijing Society for Breast Disease Prevention and Treatment
  • Vice Chair, National Expert Committee on Breast Cancer Integration, Beijing Association for Promoting Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control
  • Standing Committee Member, Palliative Care Professional Committee, Beijing Oncology Society
  • Standing Committee Member, National Expert Committee on Breast Cancer Prevention and Control, Beijing Association for Promoting Integrated Traditional Chinese and Western Medicine for Chronic Disease Prevention and Control
  • Standing Committee Member, Surgical Professional Committee, Beijing Society for Breast Disease Prevention and Treatment
  • Standing Committee Member, Translational Medicine Professional Committee, Beijing Society for Breast Disease Prevention and Treatment

Frequently asked questions

What does Dr. Li Yanping specialize in?

Specializes in breast-conserving surgery, modified radical mastectomy, sentinel lymph node biopsy, and comprehensive treatment including neoadjuvant, adjuvant, endocrine, and targeted therapy; also performs minimally invasive treatment for benign breast tumors, especially for non-palpable suspicious malignant lesions using ultrasound- or mammography-guided wire localization.

Which hospital and department is Dr. Li Yanping in?

Breast Surgery Department at Beijing Shijitan Hospital

Sources

Dr. Li Yanping has not reviewed this page. Request a correction or removal.